Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08XVR
|
|||
| Former ID |
DIB002694
|
|||
| Drug Name |
Baminercept
|
|||
| Synonyms |
BG-9924; Soluble lymphotoxin beta receptor, Biogen; Soluble lymphotoxin beta receptor, Biogen Idec
Click to Show/Hide
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Phase 2 | [1] | |
| Company |
Biogen Idec
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Lymphotoxin beta receptor (LTBR) | Target Info | Antagonist | [1] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| HTLV-I infection | ||||
| Viral carcinogenesis | ||||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01552681) Baminercept in Sj ren's Syndrome. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.